CA2384685A1 - Compositions pharmaceutiques destinees au traitement du psoriasis - Google Patents

Compositions pharmaceutiques destinees au traitement du psoriasis Download PDF

Info

Publication number
CA2384685A1
CA2384685A1 CA002384685A CA2384685A CA2384685A1 CA 2384685 A1 CA2384685 A1 CA 2384685A1 CA 002384685 A CA002384685 A CA 002384685A CA 2384685 A CA2384685 A CA 2384685A CA 2384685 A1 CA2384685 A1 CA 2384685A1
Authority
CA
Canada
Prior art keywords
dexrazoxane
medicament
calculated
injection
infusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002384685A
Other languages
English (en)
Inventor
Iervant Zarmanian
Jadranka Rogan-Grgas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyathus Exquirere Pharmaforschungs GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2384685A1 publication Critical patent/CA2384685A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur l'utilisation de dexrazoxane, l'isomère d de 1,2-bis(3,5-dioxopipérazin-1-yl)-propane, ou d'un sel physiologiquement acceptable de celui-ci, pour la préparation d'un médicament permettant de traiter le psoriasis.
CA002384685A 1999-09-10 2000-09-08 Compositions pharmaceutiques destinees au traitement du psoriasis Abandoned CA2384685A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ATA1558/99 1999-09-10
AT155899 1999-09-10
US18380600P 2000-02-22 2000-02-22
US60/183,806 2000-02-22
PCT/EP2000/008879 WO2001019358A2 (fr) 1999-09-10 2000-09-08 Compositions pharmaceutiques destinees au traitement du psoriasis

Publications (1)

Publication Number Publication Date
CA2384685A1 true CA2384685A1 (fr) 2001-03-22

Family

ID=25596169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002384685A Abandoned CA2384685A1 (fr) 1999-09-10 2000-09-08 Compositions pharmaceutiques destinees au traitement du psoriasis

Country Status (16)

Country Link
EP (1) EP1214073A2 (fr)
KR (1) KR20020035131A (fr)
CN (1) CN1378451A (fr)
AU (1) AU7286500A (fr)
BG (1) BG106428A (fr)
BR (1) BR0013921A (fr)
CA (1) CA2384685A1 (fr)
CZ (1) CZ2002729A3 (fr)
EE (1) EE04871B1 (fr)
HR (1) HRPK20020201B1 (fr)
HU (1) HUP0202791A3 (fr)
MX (1) MXPA02002486A (fr)
PL (1) PL354980A1 (fr)
RU (1) RU2002106874A (fr)
SK (1) SK2802002A3 (fr)
WO (1) WO2001019358A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053523A1 (fr) * 2019-09-18 2021-03-25 Tryp Therapeutics Compositions et procédés pour améliorer l'effet thérapeutique de bis-dioxopipérazines
EP4497436A4 (fr) 2022-03-22 2025-08-06 Univ Kyoto Médicament thérapeutique ou prophylactique contre le syndrome de l'x fragile

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4963679A (en) * 1988-02-17 1990-10-16 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
CA2167805A1 (fr) * 1993-07-23 1995-02-02 L. David Tomei Methode pour traiter l'apoptose et les troubles associes

Also Published As

Publication number Publication date
BR0013921A (pt) 2002-05-14
WO2001019358A3 (fr) 2001-10-04
BG106428A (en) 2003-04-30
EP1214073A2 (fr) 2002-06-19
MXPA02002486A (es) 2004-09-10
CN1378451A (zh) 2002-11-06
HUP0202791A3 (en) 2003-02-28
HRPK20020201B1 (en) 2004-08-31
SK2802002A3 (en) 2003-02-04
KR20020035131A (ko) 2002-05-09
AU7286500A (en) 2001-04-17
RU2002106874A (ru) 2003-11-20
PL354980A1 (en) 2004-03-22
EE04871B1 (et) 2007-08-15
HUP0202791A2 (hu) 2003-01-28
EE200200128A (et) 2003-04-15
HRP20020201A2 (en) 2003-06-30
CZ2002729A3 (cs) 2002-07-17
WO2001019358A2 (fr) 2001-03-22

Similar Documents

Publication Publication Date Title
US5374661A (en) Composition and method for transdermal delivery of diclofenac
EP2481747A1 (fr) Procédés de traitement des bouffées vasomotrices au moyen d'agonistes sélectifs du récepteur alpha-2-adrénergique
JPS62246515A (ja) タモキシフエン又はその製薬上認容性塩を含有する乾癬の治療剤
KR20050089740A (ko) 주사 치료를 위한 국소적 제형
EP3664818B1 (fr) Compositions de décongestionnant nasal comprenant du menthol, du dexpanthénol et du hyaluronate de sodium
WO2008025543A1 (fr) Compositions pharmaceutiques destinées au traitement des infections fongiques
AU2020275208B2 (en) Formulation of delgocitinib in the form of a cream
US5278172A (en) Method and composition for treating tendon or joint inflammation using a vasodilator
BR112021002156A2 (pt) tratamento de verrugas
US6693100B1 (en) Pharmaceutical compositions for treating psoriasis
US5576329A (en) Method for treating tendon or joint inflammation with papaverine HCL
WO2024239066A1 (fr) Composition pharmaceutique
EP3664786B1 (fr) Méthode de traitement du syndrome de schnitzler
JP2002530327A (ja) 硝酸ミコナゾールによる陰門膣カンジダ症を治療するための方法および装置
EP1214073A2 (fr) Compositions pharmaceutiques destinees au traitement du psoriasis
WO2021244637A1 (fr) Administration topique de propionate de 2-(diéthylamino)éthyl-2-(4-isobutylphényle) pour le traitement de maladies
EP2727595B1 (fr) Composition pharmaceutique pour traiter l'éjaculation prématurée et procédé pour traiter l'éjaculation prématurée
EP1061802B1 (fr) Formulations topiques a base de carbamazepine et leurs methodes d'utilisation
US11642328B2 (en) Creatine, its derivatives, compositions and methods of use thereof
WO2000050028A1 (fr) Compositions pour le traitement de la douleur
AU2024310497A1 (en) Composition comprising hinokitiol and zinc salt for use in the treatment of herpes labialis
JP2004026810A (ja) 鼻炎用組成物
GRAMOL Two was ronaveL BETTER.
JP2001163782A (ja) 皮膚疾患治療用外用剤
WO2001035946A2 (fr) Administration intranasale de raloxifene et de tamoxifene

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued